SCT NEWS

Single Cell Technology, Inc., a biotechnology company focused on discovering and optimizing therapeutic antibodies from diverse and unusual hosts using its proprietary Digital Antibodies engine today announced that Jim Bowlby, Chief Operations Officer, will present at the Ninth Annual PEGS, the essential protein engineering summit, Conference 2013, held April 29 to May 3, 2013, in Boston, MA. After Mr. Bowlby provides details on recent scientific achievements and company milestones, he will be available to respond to questions and participate in one-on-one meetings with potential collaborators attending the conference.

​Event: PEGS Conference 2013, Antibody and Protein Engineering Track
Date: Monday, April 29, 2013
​Session: Human B-Cell Derived Antibody Platforms: Introducing Digital Antibodies
Time: 11:30 am EDT
Location: Seaport World Trade Center Boston, MA
​Conference Link: ​​www.pegsummit.com/Antibody-Engineering-Partnering

Single Cell Technology (SCT) is a biotechnology company that has developed a new and revolutionary approach to antibody discovery. Their Digital Antibodies engine is able to analyze the kinetics and sequence the mRNA from individual antibody secreting cells. Antibodies are rapidly screened against multiple molecules to measure their affinity and specificity and mRNA from the cognate light and heavy chains are sequenced by Next Generation Sequencing (NGS) technology and correctly paired. In addition to human and mouse cells, SCT’s technology can be applied to any host that concentrates plasma cells in lymphoid tissues. Founders Chun-Nan Chen and Jim Bowlby integrated advances in multiple disciplines, such as wafer fabrication, molecular biology, precision mechanical engineering, nanotechnology, image processing, NGS, and bioinformatics. SCT’s approach substantially decreases the time and investment needed to discover high quality therapeutic and diagnostic antibodies.

​This news release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The inclusion of forward-looking statements should not be regarded as a representation that either of the companies’ plans or objectives will be achieved. Forward-looking statements involve inherent risks and uncertainties and a number of important factors could cause actual results to differ materially from those contained in any such forward-looking statement. These factors include, but are not limited to, uncertainties associated with: drug development and regulatory review process, scientific discovery process, competition, pricing environment, financing, intellectual property, and the evolution of the market for innovative antibody discovery. The companies undertake no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.